8-K: Co-Diagnostics Announces 1-for-30 Reverse Stock Split

Co-Diagnostics, Inc. will implement a 1-for-30 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Stockholders approved an amendment for a reverse stock split ratio between 1-for-2 and 1-for-30 on December 5, 2025.
• The Board of Directors approved a 1-for-30 reverse stock split ratio on December 29, 2025.
• The amendment was filed with the Utah Secretary of State on December 29, 2025, becoming effective at 11:59 pm Mountain Time on January 1, 2026.
• Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market upon market open on January 2, 2026.
• Every thirty shares of common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.001 per share.
• Fractional shares will not be issued; instead, the number of shares will be rounded up to the next whole number.
• The reverse stock split will not modify the rights or preferences of the common stock.
• Immediately after the reverse stock split becomes effective, there will be approximately 2,095,031 shares of common stock issued and outstanding.
• The common shares will trade under a new CUSIP number, 189763204, effective January 2, 2026, and continue to trade under the symbol CODX.
• All stock options and warrants outstanding immediately prior to the reverse stock split have been proportionally adjusted.
• VStock Transfer, LLC has been appointed as the exchange agent for the reverse stock split.

Sentiment

Score: 3

Explanation: While necessary for Nasdaq compliance, a reverse stock split typically signals underlying issues with the company's valuation and stock performance. It's a reactive measure rather than a proactive growth indicator, and carries the risk of not achieving or maintaining compliance.

Positives

• The reverse stock split is intended to enable the company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, preserving market access and liquidity.
• Fractional shares will be rounded up to the next whole share, which is a beneficial outcome for stockholders who would otherwise be entitled to fractional shares.

Negatives

• A reverse stock split often indicates a significantly low share price, which can be perceived negatively by investors and may reflect underlying business challenges.
• The necessity of a reverse split suggests the company has struggled to maintain a higher stock valuation organically.

Risks

• There is no assurance that implementing a reverse stock split will result in the company regaining compliance with Nasdaq listing requirements.
• Even if compliance is regained, there is no assurance that the company will be able to maintain such compliance.

Future Outlook

The reverse stock split is intended to enable the company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. However, there is no assurance that this will be successful or that compliance will be maintained.

Management Comments

• "Co-Diagnostics, Inc. (Nasdaq: CODX) (Co-Dx or the Company), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the Amendment) to effect a reverse stock split of its common stock at a ratio of 1-for-30 shares."
• "The reverse stock split is intended to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market."

Industry Context

Reverse stock splits are a common corporate action taken by companies whose stock price has fallen below minimum exchange listing requirements, such as Nasdaq's $1.00 bid price rule. This move is typically a defensive strategy to avoid delisting and maintain access to broader capital markets and investor liquidity. Many small-cap biotechnology or diagnostics companies, especially those in development phases or facing market headwinds, may resort to such measures to preserve their listing status.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism for companies to address minimum bid price deficiencies for exchange listing, similar to actions taken by companies like Sesen Bio (SESN) and Sorrento Therapeutics (SRNE) to maintain Nasdaq compliance.
• The 1-for-30 ratio is at the higher end of typical reverse split ratios, which often range from 1-for-2 to 1-for-10, indicating a significant need to boost the per-share price.
• The rounding up of fractional shares is a shareholder-friendly approach, as some companies opt to pay cash in lieu of fractional shares, which can be less favorable.

Corporate Governance

Stakeholder Impact

• Shareholders: Will see their number of shares decrease by a factor of 30, but the per-share price is expected to increase proportionally. Fractional shares are rounded up, which is beneficial. The primary impact is the potential for continued Nasdaq listing, preserving liquidity.
• Employees (with equity incentives): Stock options and warrants will be proportionally adjusted, meaning fewer shares at a higher exercise price, maintaining the overall value of their equity incentives.
• Nasdaq: The action is intended to satisfy Nasdaq's minimum bid price requirement, maintaining the company's listing on the exchange.

Next Steps

• Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market upon market open on January 2, 2026.
• The company will need to monitor its stock price to ensure it regains and maintains compliance with Nasdaq's minimum bid price requirement.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to maintain Nasdaq listing, which is crucial for liquidity and investor access. However, it does not fundamentally change the company's underlying business or financial health. While it addresses a technical listing requirement, it often reflects a struggling stock price. Investors should hold to see if the company can leverage its continued listing to improve its operational performance and valuation, but new investment based solely on this action is not warranted without further positive business developments.

Keywords

Co-Diagnostics, CODX, reverse stock split, Nasdaq compliance, corporate action, share consolidation, molecular diagnostics, SEC filing, 8-K